Within the STS cohort, oncogenic BRCA2 mutations were identified in patients diagnosed with leiomyosarcoma (n=7), sarcoma NOS (n=6), angiosarcoma (n=3), epithelioid sarcoma (n=2), embryonal rhabdomyosarcoma (n=2), radiation-associated sarcoma (n=1), round cell sarcoma NOS (n=1), solitary fibrous tumor (n=1), undifferentiated pleomorphic sarcoma (n=1), and dedifferentiated liposarcoma (n=1). This evidence concerns the gene BRCA2 and solitary fibrous tumor.